Home » Healthcare » Pharmaceuticals » Mantle Cell Lymphoma Treatment Market

Mantle Cell Lymphoma Treatment Market By Mechanism Of Action (Bruton’s Tyrosine Kinase Blocker (Ibrutinib), Angiogenesis Inhibitor (Lenalidomide), CD20 Antigen Inhibitor (Rituximab), mTOR Protein Inhibitor (Temsirolimus), Proteasome Inhibitors (Bortezomib), Phase III Drug, Tabular Representation Of Phase II And I Drugs) – Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Summary
Table Of Content

Market Insights

The World Health Organization has reported the incidence rate of mantle cell lymphoma globally as 0.5 cases per 100,000 people. Mantle cell lymphoma has an aggressive etiology that usually commences with the enlargement of a lymph node and progresses to metastasis to other organs such as the bone marrow, gastrointestinal tract, and liver. Mantle cell lymphoma is resistant to chemotherapeutic drug treatment, so a targeted treatment approach has been adopted with promising drugs in the product pipeline with better efficacy and safety, e.g., Zydelig, Gazyva, Abemaciclib, and KTE-C19.

To understand the drug regimen used for the treatment of mantle cell lymphoma, the drugs are segmented on the basis of their mechanisms of action: Bruton’s Tyrosine Kinase Blocker (ibrutinib), Angiogenesis Inhibitor (lenalidomide), CD20 Antigen Inhibitor (rituximab), mTOR Protein Inhibitor (temsirolimus), and Proteasome Inhibitors (bortezomib). A brief description of the market size and forecast is available for the above segment.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

To understand the performance of drugs employed for the treatment of mantle cell lymphoma in the regional segments, their respective major countries have been considered in the segment.

North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

Country-level cross-sectional market estimates and forecasts for the geography segment have been included in the scope of the report.

The most important aspect is to understand that a promising pipeline will result in competition among the prominent players to have a significant hold on the mantle cell. In order to understand the competitive environment in the development of drugs for the treatment of mantle cell lymphoma, we need to consider the competitive landscape. The latest mergers or acquisitions and purchases of promising drug molecules are mentioned in the company profile section. The major players in the global mantle cell lymphoma treatment market are Celgene Corporation, Abbvie, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc., Johnson & Johnson, and F. Hoffmann-La Roche Ltd.

Based on the mechanism of action, the mantle cell lymphoma treatment market is categorized into:

Bruton’s Tyrosine Kinase Blocker (Ibrutinib)
angiogenesis inhibitor (Lenalidomide)
CD20 Antigen Inhibitor (Rituximab)
mTOR Protein Inhibitor (Temsirolimus)
Bortezomib (Proteasome Inhibitors)
Phase III drug
Acalabrutinib
Bendamustine, Rituximab, and Ibrutinib (Qualitative Information)
Ibrutinib/Venetoclax (qualitative information)
Lenalidomide and Rituximab (Qualitative Information)
Rituximab/Bortezomib (qualitative information)
Tabular Representation of Phase II and I Drugs

Mantle cell lymphoma is distinguished by the overexpression of cyclin D1, which is engaged in the stimulation of cell growth due to the translocation being caused between chromosomes 11 and 14. The occurrence of mantle cell lymphoma is approximately 3–6% of newly diagnosed cases of non-Hodgkin’s lymphoma. It is metastatic in nature, with clinical manifestations reported as highly aggressive and involving the extranodal engagement of the gastrointestinal tract and bone marrow. Rituximab has been approved as the first line of treatment along with chemotherapy drugs such as cyclophosphamide, doxorubicin, vincristine, and prednisone.

The dominance of rituximab is due to the increasing number of non-Hodgkins patients diagnosed with CD20 antigen, considered a marker for mantle cell lymphoma. Obinutuzumab (Roche) will be considered to replace rituximab for the treatment of mantle cell lymphoma. Bortezomib and lenalidomide will most likely be subjected to generic completion during the forecast period of 2017–2025. Ibrutinib will be showcasing significant growth and is set to be the market leader in the treatment of mantle cell lymphoma due to the increasing cases of relapsed mantle cell lymphoma and its ability to promote apoptosis of the tumor cells. The prominent players in the mantle cell lymphoma treatment market are Bristol-Myers Squibb Company, Abbvie, Inc., Celgene Corporation, Amgen, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Eli Lilly and Company, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, and F. Hoffmann-La Roche Ltd.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

North America is currently dominating the global market for mantle cell lymphoma treatment. According to the research findings of the Leukemia and Lymphoma Society, in 2014, there were around 4,200 cases of mantle cell lymphoma. The advancement in diagnostic procedures has resulted in the efficient mapping of mantle cell lymphoma cases in patients suffering from non-Hodgkin’s lymphoma, which benefits the U.S. market. The market growth in Europe is mainly attributed to the increase in patients over 60 years of age diagnosed with mantle cell lymphoma. The European Medicines Agency provides a favorable regulatory environment for drugs used to treat mantle cell lymphoma. Asia Pacific will enjoy impressive market growth due to the increasing number of patients suffering from mantle cell lymphoma, which shows a relative association with Borrelia burgdorferi infection and genetic predisposition. The Asian Pacific market will reap the profits from the generic competition that will be faced by bortezomib and lenalidomide during the period 2015–2025. High spending to raise government-aided hospitals and research centers to treat blood malignancies drives growth in the Middle East, Africa, and Latin America.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Mantle Cell Lymphoma Treatment Market Portraiture
2.1.1. Global Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2016 (Value %)
2.1.2. Global Mantle Cell Lymphoma Treatment Market, by Geography, 2016 (Value %)

Chapter 3. Mantle Cell Lymphoma Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Top 3 Countries: Global Mantle Cell Lymphoma Treatment Market, 2015-2025 (US$ Mn)
3.7. Competitive Landscape: Global Mantle Cell Lymphoma Treatment Market, by Key Players, 2015-2025 (US$ Mn)

Chapter 4. Global Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2016
4.3. Bruton’s Tyrosine Kinase Blocker (Ibrutinib)
4.4. Angiogenesis Inhibitor (Lenalidomide)
4.5. CD20 Antigen Inhibitor (Rituximab)
4.6. mTOR Protein Inhibitor (Temsirolimus)
4.7. Proteasome Inhibitors (Bortezomib)
4.8. Phase III Drug
4.8.1. Acalabrutinib
4.8.2. Bendamustine/Rituximab/Ibrutinib (Qualitative Information)
4.8.3. Ibrutinib/Venetoclax (Qualitative Information)
4.8.4. Lenalidomide/Rituximab (Qualitative Information)
4.8.5. Rituximab/Bortezomib (Qualitative Information)
4.9. Tabular Representation of Phase II and I Drugs

Chapter 5. Global Mantle Cell Lymphoma Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. North America Mantle Cell Lymphoma Treatment Market Analysis, 2015 – 2025
5.2.1. North America Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
5.2.2. North America Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.3. Europe Mantle Cell Lymphoma Treatment Market Analysis, 2015 – 2025
5.3.1. Europe Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
5.3.2. Europe Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.4. Asia Pacific Mantle Cell Lymphoma Treatment Market Analysis, 2015 – 2025
5.4.1. Asia Pacific Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
5.4.2. Asia Pacific Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.5. Latin America Mantle Cell Lymphoma Treatment Market Analysis, 2015 – 2025
5.5.1. Latin America Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
5.5.2. Latin America Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.6. Middle East & Africa Mantle Cell Lymphoma Treatment Market Analysis, 2015 – 2025
5.6.1. Middle East and Africa Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
5.6.2. Middle East and Africa Mantle Cell Lymphoma Treatment Market, by Region, 2015 – 2025 (US$ Mn)

Chapter 6. Company Profiles
6.1. Abbvie, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Amgen, Inc.
6.3. Astellas Pharma, Inc.
6.4. Biogen, Inc.
6.5. Bayer AG
6.6. Bristol-Myers Squibb Company
6.7. Celgene Corporation
6.8. Eli Lilly and Company
6.9. GlaxoSmithKline Plc
6.10. Gilead Sciences, Inc.
6.11. Johnson and Johnson
6.12. F.Hoffman La Roche Ltd.

List of Figures

FIG. 1 Mantle Cell Lymphoma Treatment: Market Segmentation
FIG. 2 Global Mantle Cell Lymphoma Treatment Market Share, by Mechanism of Action, 2016 (Value %)
FIG. 3 Global Mantle Cell Lymphoma Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Ibrutinib Market for Mantle Cell Lymphoma Treatment, 2015 – 2025 (US$ Mn)
FIG. 7 Global Lenalidomide Market for Mantle Cell Lymphoma Treatment, 2015 – 2025 (US$ Mn)
FIG. 8 Global Rituximab Market for Mantle Cell Lymphoma Treatment, 2015 – 2025 (US$ Mn)
FIG. 9 Global Temsirolimus Market for Mantle Cell Lymphoma Treatment, 2015 – 2025 (US$ Mn)
FIG. 10 Global Bortezomib Market for Mantle Cell Lymphoma Treatment, 2015 – 2025 (US$ Mn)
FIG. 11 U.S. Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 12 Canada Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 13 U.K. Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 14 Germany Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 15 Rest of Europe Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 16 Japan Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 17 China Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 18 India Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 19 Rest of Asia Pacific Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 20 Brazil Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 21 Mexico Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 22 Rest of Latin America Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 23 GCC Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 24 Rest of Middle East and Africa Mantle Cell Lymphoma Treatment Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Mantle Cell Lymphoma Treatment Market Portraiture
TABLE 2 Global Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
TABLE 3 Global Mantle Cell Lymphoma Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 4 North America Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
TABLE 5 North America Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Mantle Cell Lymphoma Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East And Africa Mantle Cell Lymphoma Treatment Market, by Mechanism of Action, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East And Africa Mantle Cell Lymphoma Treatment Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 14 Abbvie, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Astellas Pharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Biogen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Celgene Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 GlaxoSmithKline Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Gilead Sciences, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Johnson and Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 F.Hoffman La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Frequently Asked Question

What is the size of Mantle Cell Lymphoma Treatment Market?

The market for Mantle Cell Lymphoma Treatment Market is expected to reach USD$ XX in 2025.

What is the Mantle Cell Lymphoma Treatment Market CAGR?

The Mantle Cell Lymphoma Treatment Market is expected to see significant CAGR growth over the coming years, at 4.8 %.

What is the Forecast period considered for Mantle Cell Lymphoma Treatment Market?

The report is forecasted from 2017 -2025.

What is the base year considered for Mantle Cell Lymphoma Treatment Market?

The base year of this report is 2016.

Who are the major players in this market?

ACelgene Corporation, Abbvie, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company. are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –